The findings from researchers at Albert Einstein College of Medicine of Yeshiva University in US and the Icahn School of Medicine at Mount Sinai could lead to novel therapies for diseases or conditions in which the red blood cell production is thrown out of balance.
"Our findings offer intriguing new insights into how the body maintains a healthy balance of red blood cells," said study leader Paul Frenette, professor of medicine and of cell biology and director of the Ruth L and David S Gottesman Institute for Stem Cell and Regenerative Medicine Research at Einstein.
"This understanding may ultimately help us to devise new therapies for conditions that lead to abnormal RBC counts, such as hemolytic anemia, polycythemia vera, and acute blood loss, plus aid recovery from chemotherapy and bone marrow transplantation," he said.
Previous research has shown that bone marrow macrophages express a cell surface molecule called sialoadhesin, or CD169 - a target that could be used for selectively eliminating macrophages from bone marrow.
"After we depleted the macrophages in the bone marrow, we discovered that we had also depleted CD169-positive macrophages present in the spleen and liver," Frenette said.
"It turns out that the macrophages in these two organs are quite important in removing old red blood cells from the peripheral circulation. Taken together, the findings show that these macrophages have a dual role, both producing and clearing red blood cells," he said.
Using a mouse model of polycythemia vera, they found that depleting CD169-positive macrophages in bone marrow normalises the RBC count.
The study was published in the journal Nature Medicine.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
